This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In response, the PPD clinicalresearch business of Thermo Fisher Scientific conducted its third global survey of 150 drug developers to capture a comprehensive view of these evolving trends. Furthermore, the development of innovative therapies often necessitates intricate protocols, adding layers of complexity to trial management.
In the past, these developers mostly used in-house resources for their clinical monitoring and site management capabilities, whereas today they often prefer functional service provider (FSP) or full-service outsourcing (FSO) models, or a hybrid of the two, to ensure on-time and on-budget delivery of clinical operations.
The drug development industry faces rising costs and increasingly complex protocols as top challenges, with 49% of developers citing costs as their primary concern and 39% pointing to protocol complexity as a key hurdle, according to a recent survey of 150 drug developers worldwide by the PPD clinicalresearch business of Thermo Fisher Scientific.
The PPD clinicalresearch business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.
To get a pulse on the changing industry, the PPD clinicalresearch business of Thermo Fisher Scientific surveyed 150 biotech and biopharma leaders for the second year in a row to illuminate industry trends, challenges and sentiments. Download the full 2023 report to access all the insights.
The PPD clinicalresearch business of Thermo Fisher Scientific has surveyed more than 150 drug developers around the globe to gather annual data on trends in pharmaceutical research and development. Respondents shared sentiments about current challenges within their organizations and the broader industry.
The PPD clinicalresearch business of Thermo Fisher Scientific has surveyed more than 150 drug developers around the globe to gather annual data on trends in pharmaceutical research and development. In Asia , personalized and precision medicine has become the driving force behind transformative clinical trials.
With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely. BetterLife conducts patient centric study via a fully remote clinical trial. All of these technologies can be used on a variety of devices. Source link.
Efficient and effective clinical operations are the backbone of successful clinical trials, and today’s biopharmaceutical, biotech and medical device organizations have a range of options to meet their needs in this critical area.
Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.
is an innovative, private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Our vision is to identify, develop and deliver to patients important new therapies for diseases with significant unmet need. .
Adastra Pharmaceuticals Inc.
.
“We are eager to learn more about which patients develop resistance to CDK 4 & 6 inhibitors, the potential underlying mechanisms, and ways in which such resistance can be overcome, in order to improve the application of this potentially life-prolonging therapy. .
View original content to download multimedia: [link].
Currently, oral treatment options for plaque psoriasis are limited, and many patients with moderate-to-severe psoriasis are receiving systemic injectable therapies. We confidently believe in the benefits of oral orismilast, and the IND approval marks a significant milestone in our clinical development.” SOURCE UNION therapeutics.
Voclosporin follows the recent approval of belimumab by the FDA as new therapies indicated for lupus nephritis – both within the past month.
View original content to download multimedia: [link].
SOURCE Lupus Research Alliance.
[1] Lupus and Kidney Disease (Lupus Nephritis).
To keep a pulse on this rapidly changing industry, the PPD clinicalresearch business of Thermo Fisher Scientific surveyed 150 leaders in the biopharma and biotech industries for the second consecutive year. Accordingly, oncology is the leading therapeutic area for drug development reported in our survey, regardless of sponsor size.
For a developer using an FSO model but looking to evolve the way they undertake clinical trials, a bespoke FSP/FSO hybrid solution can provide a smooth transition to FSP outsourcing. This approach enables unbroken continuity of support and resources across clinical trial operations.
The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. Department of Defense Medical Research Program.
View original content to download multimedia: [link].
About Lupus.
.
.
Glooko is transforming digital health by connecting people with diabetes and related conditions and their health care professionals, enabling telehealth, clinicalresearch, and improved collaboration. View original content to download multimedia: [link]. About Glooko Inc. of Health and Human Services ; 2020. Source link.
During her years of practice, Dr. Cooper has received numerous awards for her outstanding surgical techniques, teaching excellence, clinicalresearch and patient satisfaction, and has been named one of the Best Doctors in America by St.
View original content to download multimedia: [link].
One of the most important factors to consider during the course of your early-phase clinicalresearch is drug-drug interactions (DDIs), which occurs when one drug alters the effect of another, either by reducing its effectiveness or elevating systemic concentrations to potentially dangerous levelsultimately causing side effects.
While the world is facing a severe shortage of specific antiviral drugs, a new treatment developed by Asclepius Meditec highlights the potential of hydrogen-oxygen therapy in tackling COVID-19. Founded in 2011, Shanghai Asclepius Meditec is the first company globally to launch clinicalresearch on hydrogen-oxygen medicine.
It is funded by the world’s leading charities dedicated to diabetes research, JDRF, and Diabetes UK, guided by both organizations’ strong commitment to facilitate deep interrogation of consolidated community-wide trial data as a means to accelerate clinicalresearch and therapeutic development for T1D.
Covid-19 command center aims to accelerate clinicalresearch by individual sponsors to combat disease. Dive into Medidata’s white paper to find out the best practices and new testing methods clinical trial sponsors are using to immerse patients into clinical trials for a better patient experience and for more enhanced data quality.
The PPD clinicalresearch business of Thermo Fisher Scientific has conducted a comprehensive survey involving 150 drug developers from around the world. This year’s findings reveal a nuanced landscape where rising clinical trial costs, complex protocol designs and patient recruitment issues have emerged as significant challenges.
To better understand current challenges and their impact, the PPD clinicalresearch business of Thermo Fisher Scientific surveyed global drug developers on the current state of the industry. This is especially critical in managing complex therapies, where precision and safety are paramount.
Bespoke solutions are critical for successful drug development because each clinicalresearch project has unique goals and challenges. We provide the depth and breadth of expertise required to help our clients meet their timelines and accelerate the development of life-changing therapies.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content